利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.037 秒)

    ANTI-C-MET ANTIBODY HAVING HGF ACTIVITY AND USE THEREOF
    1.
    发明申请
    ANTI-C-MET ANTIBODY HAVING HGF ACTIVITY AND USE THEREOF 有权
    具有HGF活性的抗C-MET抗体及其用途

    公开(公告)号：US20140193431A1

    公开(公告)日：2014-07-10

    申请号：US14123533

    申请日：2012-06-04

    申请人： Young Woo Park ,  KiWon Jo ,  Chan Woong Park ,  Seok Ho Yoo ,  Myeoung Hee Jang ,  Hye Nan Kim ,  Seon Ha Yun ,  Kyu Won Cho ,  Mi Ra Park

    发明人： Young Woo Park ,  KiWon Jo ,  Chan Woong Park ,  Seok Ho Yoo ,  Myeoung Hee Jang ,  Hye Nan Kim ,  Seon Ha Yun ,  Kyu Won Cho ,  Mi Ra Park

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2317/94

    摘要： Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.

    摘要翻译： 公开了包含与c-Met特异性结合的人互补决定区（CDR）的人抗体和框架区（FR），编码人抗体的多核苷酸，包含多核苷酸的表达载体，转化了 表达载体，通过培养转化体生产人抗体B7的方法，包含人抗体作为活性成分的伤口愈合组合物，包含抗体作为活性成分的细胞再生组合物和包含药物连接的药物偶联物 对人抗体。 c-Met特异性人抗体可用作可用作伤口愈合组合物的HGF模拟物。 该抗体可广泛用于确定通过激活HGF或其他疾病治疗的各种疾病的治疗和预后，包括神经元梗死，进行性肾病，肝硬化，肺纤维化，肾损伤，肝损伤，肺损伤和溃疡性创伤 c-Met。

    PHARMACEUTICAL COMPOSITION CONTAINING AN ENDOCYTIC MOTIF AND PROTEIN TRANSDUCTION DOMAINS FOR PREVENTING OR TREATING CANCER
    6.
    发明申请
    PHARMACEUTICAL COMPOSITION CONTAINING AN ENDOCYTIC MOTIF AND PROTEIN TRANSDUCTION DOMAINS FOR PREVENTING OR TREATING CANCER 有权
    含有内源性MOTIF的蛋白质组合物和用于预防或治疗癌症的蛋白质转染域

    公开(公告)号：US20140066375A1

    公开(公告)日：2014-03-06

    申请号：US14002600

    申请日：2012-03-02

    申请人： Young Woo Park ,  Ki Won Jo ,  Kyu Won Cho ,  Ji Hyun Park ,  Soon Sil Hyun ,  Yun Jung Park

    发明人： Young Woo Park ,  Ki Won Jo ,  Kyu Won Cho ,  Ji Hyun Park ,  Soon Sil Hyun ,  Yun Jung Park

    IPC分类号： C07K7/08 ,  C07K14/00

    CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K14/00 ,  C07K14/4753 ,  C07K2319/10

    摘要： The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.

    摘要翻译： 本发明涉及一种新的内吞基序，特别涉及包含由SEQ ID NO：1的氨基酸序列表示的基序的融合多肽。 1和蛋白质转导结构域，用于预防或治疗包括其的癌症的药物组合物，以及治疗癌症的方法，包括施用组合物的步骤。 本发明通过特异性抑制c-Met内吞作用并有效抑制与各种癌细胞的转移和生长相关的HGF / c-Met信号通路，显示抑制癌转移，浸润，血管生成和生长的作用。 因此，本发明可以应用于各种癌症的抗癌剂。